Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Hong Kong Hospital Authority, Kowloon, Hong Kong, China.
Diabetes Res Clin Pract. 2022 Sep;191:110030. doi: 10.1016/j.diabres.2022.110030. Epub 2022 Aug 4.
This systematic review aims to assess the incidence of chronic kidney disease (CKD), cardiovascular disease (CVD) and mortality in people with type 2 diabetes diagnosed <20 years.
We searched MEDLINE, Embase and Cochrane Library for longitudinal studies published between 1 January 2000 and 31 November 2021.
Seventeen studies (15 reporting CKD, 3 reporting CVD, 5 reporting mortality) from seven countries of sample size ranging between 96 and 4,141 were eligible. Most studies were conducted in North America and Europe (n = 14). Diabetes duration at enrolment varied from 0 to 8.3 years and follow-up duration from 1 to 12.6 years. The incidence rates (per 1,000 person-year) of albuminuria ranged between 12.4 and 114.8, macroalbuminuria or proteinuria between 10 and 35.0, end-stage kidney disease (ESKD) between 0.4 and 25.0, CVD between 3.7 and 19.5, and mortality between 1.0 and 18.6. The highest incidence rates of albuminuria, ESKD and mortality were recorded in Australian Aboriginal and Pima Indian populations. Youth-onset type 2 diabetes was associated with greater risk of developing CKD compared with type 1 diabetes in most studies.
Studies reporting CVD in youth-onset type 2 diabetes are scarce. Estimated incidence rates of CKD and mortality in youth-onset type 2 diabetes varied across different study populations, potentially higher in indigenous people. Youth with type 2 diabetes are at higher risk of adverse kidney outcomes than their type 1 counterparts. More studies are needed in regions outside of North America and Europe.
本系统评价旨在评估发病年龄<20 岁的 2 型糖尿病患者的慢性肾脏病(CKD)、心血管疾病(CVD)和死亡率。
我们检索了 MEDLINE、Embase 和 Cochrane 图书馆,以获取 2000 年 1 月 1 日至 2021 年 11 月 31 日期间发表的纵向研究。
来自七个国家的 17 项研究(15 项报告 CKD,3 项报告 CVD,5 项报告死亡率)符合纳入标准,样本量范围为 96 至 4141 人。大多数研究在北美和欧洲进行(n=14)。登记时的糖尿病病程从 0 至 8.3 年不等,随访时间从 1 至 12.6 年不等。白蛋白尿的发生率(每 1000 人年)范围为 12.4 至 114.8,大量白蛋白尿或蛋白尿为 10 至 35.0,终末期肾病(ESKD)为 0.4 至 25.0,CVD 为 3.7 至 19.5,死亡率为 1.0 至 18.6。在澳大利亚原住民和皮马印第安人群中,白蛋白尿、ESKD 和死亡率的发生率最高。与 1 型糖尿病相比,大多数研究报告 2 型糖尿病发病年龄较轻与 CKD 风险增加相关。
在青年发病的 2 型糖尿病患者中,报告 CVD 的研究较少。不同研究人群中,青年发病的 2 型糖尿病患者的 CKD 和死亡率的估计发生率有所不同,在原住民中可能更高。与 1 型糖尿病患者相比,2 型糖尿病患者的不良肾脏结局风险更高。需要在北美和欧洲以外的地区开展更多的研究。